Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapeutics for many diseases, including cancer, in clinical trials(1). One PARP inhibitor, olaparib (Lynparza(™), AstraZeneca), was recently approved by the FDA to treat ovarian cancer with BRCA mutations. BRCA1 and BRCA2 pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Med
Autors principals: Du, Yi, Yamaguchi, Hirohito, Wei, Yongkun, Hsu, Jennifer L., Wang, Hung-Ling, Hsu, Yi-Hsin, Lin, Wan-Chi, Yu, Wen-Hsuan, Leonard, Paul G., Lee, Gilbert R., Chen, Mei-Kuang, Nakai, Katsuya, Hsu, Ming-Chuan, Chen, Chun-Te, Sun, Ye, Wu, Yun, Chang, Wei-Chao, Huang, Wen-Chien, Liu, Chien-Liang, Chang, Yuan-Ching, Chen, Chung-Hsuan, Park, Morag, Jones, Philip, Hortobagyi, Gabriel N., Hung, Mien-Chie
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4754671/
https://ncbi.nlm.nih.gov/pubmed/26779812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nm.4032
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars